OVERVIEW

Leading Global Bioanalytical CRO

Aliri BIOANALYSIS

Navigating a robust regulatory environment, advancing your development program withspeed, and accessing a breadth of technical expertise are all critical factors to the success of your program. Aliri provides a range of bioanalytical lab, spatial bioanalysis, and spatial biology solutions.



BIOANALYSIS

We are committed to helping you build, execute, and optimize your drug development strategy, so you can bring life-changing therapies to market with speed. Work with our team of dedicated scientists, program managers, quality specialists, and industry experts to:

- Achieve quality data for filing your IND, NDA, and CTA with speed
- Forecast technical issues or potential roadblocks that may cause delays
- Maximize the growth of your drug discovery and development investments

OFFERING	PLATFORMS	COMPOUNDS	REGULATIONS	
Discovery	LC-MS/MS	Small molecules	GLP	VICH
Method development	LC-HRMS	Biomarkers	FDA	CVM
Method validation	LC-Fluoresence detection	OGNs therapeutics	CDER	EMA
Sample analysis	qPCR	Biologics	CBER	OECD
	CyTOF	Endogenous		

Most approaches can be combined with laser microdissection to define specific tissue regions more precisely.

SPATIAL BIOANALYSIS

Embedding spatial bioanalysis into your discovery and development strategy will help you save money and time in the long run. Our proprietary drug imaging workflows will enable you to study the distribution of drugs and biomarkers simultaneously at the site of action.

Spatial bioanalysis will allow you to:

- Gain access to unique data for strategic decision making and lead optimization
- Understand localization, quantification, and distribution of drugs at the site of action
- Study the whole-body distribution of your drug and related metabolites in animal models without any labeling
- Select the right dose, mode of administration and/or formulation to expose your organ or target of interest
- Identify the molecular component of lesions observed in toxicity studies
- Simultaneously localize and quantify of thousands of markers with your drug in the tissue microenvironment

	QMSI (QUANTITATIVE MASS SPECTROMETRY IMAGING	LASER ABLATION INDUCTIVELY COUPLED PLASMA (LA-ICP) IMAGING
OVERVIEW	Detect and quantify ionizable, label-free, small molecules in tissue selection	Detect elements from tissue section
THROUGHPUT	1–10 samples/day	1–10 samples/day
MOLECULE TYPE	Small Molecules (metabolites, amino acids, lipids from tissue selection, etc.)	Various elements
MASS ACCURACY	<1ppm	Unit mass resolution
SAMPLE PREP	Cryostat, Microtome, Histological AutoStainer	

SPATIAL BIOLOGY

Our technology enables you to discover and monitor your biomarker prevalence and organization in the tissue to characterize disease state. Partnering with us in spatial biology will give you access to a range of equipment that will:

- Provide spatially differentiated profiling of tumor driver and immuno-oncology proteins
- Discover biomarkers related to location and signaling of specific cells
- Analyze pathways across tissue structures and complexity
- Provide basis for identifying clinically relevant associations with drugs

	SPATIAL-METABOLOMICS & LIPIDOMICS	SPATIAL-PROTEOMICS	SPATIAL-TRANSCRIPTOMICS
OVERVIEW	Mass Spectrometry Imaging (MALDI-FTICR, 2XR - Solarix)	Imaging Mass Cytometry (Hyperion) GeoMX DSP Multiplex Immunostaining	Visium and Visium HD GeoMX DSP RNAscope
MOLECULE TYPE	Small molecules, lipids, metabolites, peptides, neurotransmitters	Protein	RNA ASO / siRNA
THROUGHPUT	1-10 samples/day	1-4 samples/day	1-10 samples/day

DATA SCIENCE & ARTIFICIAL INTELLIGENCE

Our team has integrated Artificial Intelligence (AI) with spatial-omics data to transform drug candidate selection and de-risk drug development. By leveraging AI-driven analysis, we enable earlier and more accurate predictions of the efficacy of targeted therapies and put critical data in our clients' hands for strategic decision-making. Our proprietary AI algorithms process complex biological datasets to uncover the mechanisms of action at the single-cell level, offering a level of certainty and efficiency that traditional methods cannot match. By integrating genomic, proteomic, and metabolomic insights, this approach accelerates biomarker discovery, enhances drug target validation, and optimizes the selection of high-potential candidates for clinical success.

Unlike conventional bioanalysis methods, which rely on manual data interpretation and bulk analysis, Aliri's AI-powered spatial-omics platform delivers high-resolution, single-cell insights at an unprecedented scale. Our custom AI scripts automate complex biological analyses, improving predictive accuracy, efficiency, and reproducibility. By integrating AI with multi-omics datasets, we provide spatially resolved biomarker intelligence, allowing sponsors to better understand drug mechanisms of action, patient stratification, and therapeutic response predictions. This AI-driven approach de-risks drug development, saving time and costs while increasing the likelihood of clinical success, ultimately providing our clients with a distinct competitive edge in precision medicine and translational research.

SCHEDULE A MEETING to learn how our team can help develop a bioanalytical strategy.

we deliver
data for life >

Aliri
aliribio.com
USA: +1 (719) 593-1165
FRANCE: +33 (0)374 095 546